- Home
- ABTS vs KPRX Comparison
ABTS vs KPRX Comparison
Compare ABTS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- KPRX
- Stock Information
- Founded
- ABTS 2010
- KPRX 1998
- Country
- ABTS Hong Kong
- KPRX United States
- Employees
- ABTS N/A
- KPRX N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ABTS Technology
- KPRX Health Care
- Exchange
- ABTS Nasdaq
- KPRX Nasdaq
- Market Cap
- ABTS 8.9M
- KPRX 8.7M
- IPO Year
- ABTS N/A
- KPRX N/A
- Fundamental
- Price
- ABTS $3.48
- KPRX $2.71
- Analyst Decision
- ABTS
- KPRX Strong Buy
- Analyst Count
- ABTS 0
- KPRX 1
- Target Price
- ABTS N/A
- KPRX $10.00
- AVG Volume (30 Days)
- ABTS 8.7K
- KPRX 80.3K
- Earning Date
- ABTS 08-13-2025
- KPRX 11-07-2025
- Dividend Yield
- ABTS N/A
- KPRX N/A
- EPS Growth
- ABTS N/A
- KPRX N/A
- EPS
- ABTS N/A
- KPRX N/A
- Revenue
- ABTS $7,037,156.00
- KPRX N/A
- Revenue This Year
- ABTS N/A
- KPRX N/A
- Revenue Next Year
- ABTS N/A
- KPRX N/A
- P/E Ratio
- ABTS N/A
- KPRX N/A
- Revenue Growth
- ABTS 31.69
- KPRX N/A
- 52 Week Low
- ABTS $1.35
- KPRX $2.25
- 52 Week High
- ABTS $14.10
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- ABTS 38.61
- KPRX 48.49
- Support Level
- ABTS $3.40
- KPRX $2.67
- Resistance Level
- ABTS $3.89
- KPRX $2.90
- Average True Range (ATR)
- ABTS 0.25
- KPRX 0.14
- MACD
- ABTS -0.03
- KPRX 0.01
- Stochastic Oscillator
- ABTS 9.54
- KPRX 39.13
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.